In 2023, the treatment success rate for multidrug-resistant tuberculosis (MDR-TB) in China stood at 40%. Forecasts from 2024 to 2028 show a gradual decline, with rates falling from 39% in 2024 to 37% in 2028. This consistent decrease indicates ongoing challenges in managing MDR-TB effectively in the region. Year-on-year variations demonstrate a declining trend, with a small reduction percentage per annum, highlighting the need for enhanced treatment strategies.

Future trends to watch for:

Advancements in treatment protocols and drug development that could potentially reverse the declining success rate.
Increased funding and resources from public health initiatives targeting TB control.
Technological innovations such as rapid diagnostics and personalized medicine approaches.